CLINICAL TRIALS PROFILE FOR QBREXZA
✉ Email this page to a colleague
All Clinical Trials for QBREXZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04159610 ↗ | Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis | Not yet recruiting | Therapeutics, Inc. | Phase 2 | 2022-07-01 | The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions. |
| NCT04159610 ↗ | Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis | Not yet recruiting | Dr. August Wolff GmbH & Co. KG Arzneimittel | Phase 2 | 2022-07-01 | The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions. |
| NCT04906655 ↗ | An Open Label Study for Palmar Hyperhydrosis | Completed | Virginia Clinical Research, Inc. | Phase 2 | 2020-10-01 | The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis |
| NCT04906655 ↗ | An Open Label Study for Palmar Hyperhydrosis | Completed | Pariser, Robert J., M.D. | Phase 2 | 2020-10-01 | The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis |
| NCT04924036 ↗ | Qbrexza Cloths for Hyperhidrosis of Amputation Sites | Recruiting | University of Utah | Phase 2 | 2021-09-27 | This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial using Qbrexza Cloths to treat hyperhidrosis of amputation sites. There is a 2 week screening period where patients will use an activity monitor to establish baseline activity level, then patients will be randomized to receive either Qbrexza cloths or placebo for 4 weeks, then a 2 week washout, and then a 4-week cross-over treatment period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for QBREXZA
Condition Name
Clinical Trial Locations for QBREXZA
Trials by Country
Clinical Trial Progress for QBREXZA
Clinical Trial Phase
Clinical Trial Sponsors for QBREXZA
Sponsor Name
